8 results on '"Rauen KA"'
Search Results
2. RASopathies - what they reveal about RAS/MAPK signaling in skeletal muscle development.
- Author
-
Rauen KA and Tidyman WE
- Subjects
- Humans, Animals, Signal Transduction, MAP Kinase Signaling System, Mitogen-Activated Protein Kinases metabolism, Disease Models, Animal, Muscle, Skeletal metabolism, Muscle, Skeletal pathology, ras Proteins metabolism, Muscle Development genetics
- Abstract
RASopathies are rare developmental genetic syndromes caused by germline pathogenic variants in genes that encode components of the RAS/mitogen-activated protein kinase (MAPK) signal transduction pathway. Although the incidence of each RASopathy syndrome is rare, collectively, they represent one of the largest groups of multiple congenital anomaly syndromes and have severe developmental consequences. Here, we review our understanding of how RAS/MAPK dysregulation in RASopathies impacts skeletal muscle development and the importance of RAS/MAPK pathway regulation for embryonic myogenesis. We also discuss the complex interactions of this pathway with other intracellular signaling pathways in the regulation of skeletal muscle development and growth, and the opportunities that RASopathy animal models provide for exploring the use of pathway inhibitors, typically used for cancer treatment, to correct the unique skeletal myopathy caused by the dysregulation of this pathway., Competing Interests: Competing interests The authors declare no competing or financial interests., (© 2024. Published by The Company of Biologists Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
3. MEK-inhibitor-mediated rescue of skeletal myopathy caused by activating Hras mutation in a Costello syndrome mouse model.
- Author
-
Tidyman WE, Goodwin AF, Maeda Y, Klein OD, and Rauen KA
- Subjects
- Animals, Mice, Mitogen-Activated Protein Kinase Kinases genetics, Mitogen-Activated Protein Kinase Kinases metabolism, Mutation genetics, Phosphatidylinositol 3-Kinases metabolism, Proto-Oncogene Proteins p21(ras) genetics, Proto-Oncogene Proteins p21(ras) metabolism, Quality of Life, Costello Syndrome genetics, Costello Syndrome metabolism, Muscular Diseases
- Abstract
Costello syndrome (CS) is a congenital disorder caused by heterozygous activating germline HRAS mutations in the canonical Ras/mitogen-activated protein kinase (Ras/MAPK) pathway. CS is one of the RASopathies, a large group of syndromes caused by mutations within various components of the Ras/MAPK pathway. An important part of the phenotype that greatly impacts quality of life is hypotonia. To gain a better understanding of the mechanisms underlying hypotonia in CS, a mouse model with an activating HrasG12V allele was utilized. We identified a skeletal myopathy that was due, in part, to inhibition of embryonic myogenesis and myofiber formation, resulting in a reduction in myofiber size and number that led to reduced muscle mass and strength. In addition to hyperactivation of the Ras/MAPK and PI3K/AKT pathways, there was a significant reduction in p38 signaling, as well as global transcriptional alterations consistent with the myopathic phenotype. Inhibition of Ras/MAPK pathway signaling using a MEK inhibitor rescued the HrasG12V myopathy phenotype both in vitro and in vivo, demonstrating that increased MAPK signaling is the main cause of the muscle phenotype in CS., Competing Interests: Competing interests The authors declare no competing or financial interests., (© 2021. Published by The Company of Biologists Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
4. Defining RASopathy.
- Author
-
Rauen KA
- Subjects
- Genes, ras, Humans, Syndrome, Mitogen-Activated Protein Kinases metabolism, Signal Transduction genetics
- Abstract
The term RASopathy was originally created to describe a phenotypically similar group of medical genetic syndromes caused by germline pathogenic variants in components of the RAS/mitogen-activated protein kinase (RAS/MAPK) pathway. In defining a RASopathy syndrome, one needs to consider the complex nature of the RAS/MAPK pathway, the numerous genes and regulatory components involved, its crosstalk with other signaling pathways and the phenotypic spectrum among these syndromes. Three main guiding principles to the definition should be considered. First, a RASopathy is a clinical syndrome with overlapping phenotypic features caused by germline pathogenic variants associated with the RAS/MAPK pathway. Second, a RASopathy is caused by multiple pathogenetic mechanisms, all of which lead to a similar outcome of RAS/MAPK pathway activation/dysregulation. Finally, because a RASopathy has dysfunctional germline RAS/MAPK pathway activation/dysregulation, it may, therefore, be amenable to treatment with pathway modulators., Competing Interests: Competing interests The author declares no competing or financial interests., (© 2022. Published by The Company of Biologists Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
5. Mek1 Y130C mice recapitulate aspects of human cardio-facio-cutaneous syndrome.
- Author
-
Aoidi R, Houde N, Landry-Truchon K, Holter M, Jacquet K, Charron L, Krishnaswami SR, Yu BD, Rauen KA, Bisson N, Newbern J, and Charron J
- Subjects
- Alleles, Amino Acid Sequence, Animals, Base Sequence, Brain pathology, Cell Count, Embryo, Mammalian cytology, Facies, Fibroblasts enzymology, Gene Duplication, Glial Fibrillary Acidic Protein metabolism, Humans, MAP Kinase Kinase 1 chemistry, MAP Kinase Signaling System genetics, Mice, Mice, Mutant Strains, Oligodendrocyte Transcription Factor 2 metabolism, Ectodermal Dysplasia genetics, Failure to Thrive genetics, Heart Defects, Congenital genetics, MAP Kinase Kinase 1 genetics, Mutation genetics
- Abstract
The RAS/MAPK signaling pathway is one of the most investigated pathways, owing to its established role in numerous cellular processes and implication in cancer. Germline mutations in genes encoding members of the RAS/MAPK pathway also cause severe developmental syndromes collectively known as RASopathies. These syndromes share overlapping characteristics, including craniofacial dysmorphology, cardiac malformations, cutaneous abnormalities and developmental delay. Cardio-facio-cutaneous syndrome (CFC) is a rare RASopathy associated with mutations in BRAF , KRAS , MEK1 ( MAP2K1 ) and MEK2 ( MAP2K2 ). MEK1 and MEK2 mutations are found in ∼25% of the CFC patients and the MEK1
Y130C substitution is the most common one. However, little is known about the origins and mechanisms responsible for the development of CFC. To our knowledge, no mouse model carrying RASopathy-linked Mek1 or Mek2 gene mutations has been reported. To investigate the molecular and developmental consequences of the Mek1Y130C mutation, we generated a mouse line carrying this mutation. Analysis of mice from a Mek1 allelic series revealed that the Mek1Y130C allele expresses both wild-type and Y130C mutant forms of MEK1. However, despite reduced levels of MEK1 protein and the lower abundance of MEK1 Y130C protein than wild type, Mek1Y130C mutants showed increased ERK (MAPK) protein activation in response to growth factors, supporting a role for MEK1 Y130C in hyperactivation of the RAS/MAPK pathway, leading to CFC. Mek1Y130C mutant mice exhibited pulmonary artery stenosis, cranial dysmorphia and neurological anomalies, including increased numbers of GFAP+ astrocytes and Olig2+ oligodendrocytes in regions of the cerebral cortex. These data indicate that the Mek1Y130C mutation recapitulates major aspects of CFC, providing a new animal model to investigate the physiopathology of this RASopathy. This article has an associated First Person interview with the first author of the paper., Competing Interests: Competing interestsThe authors declare no competing or financial interests., (© 2018. Published by The Company of Biologists Ltd.)- Published
- 2018
- Full Text
- View/download PDF
6. RASopathies: unraveling mechanisms with animal models.
- Author
-
Jindal GA, Goyal Y, Burdine RD, Rauen KA, and Shvartsman SY
- Published
- 2015
- Full Text
- View/download PDF
7. RASopathies: unraveling mechanisms with animal models.
- Author
-
Jindal GA, Goyal Y, Burdine RD, Rauen KA, and Shvartsman SY
- Subjects
- Animals, Genetic Engineering, Humans, MAP Kinase Signaling System, Models, Biological, Mutation genetics, Disease Models, Animal, ras Proteins metabolism
- Abstract
RASopathies are developmental disorders caused by germline mutations in the Ras-MAPK pathway, and are characterized by a broad spectrum of functional and morphological abnormalities. The high incidence of these disorders (∼1/1000 births) motivates the development of systematic approaches for their efficient diagnosis and potential treatment. Recent advances in genome sequencing have greatly facilitated the genotyping and discovery of mutations in affected individuals, but establishing the causal relationships between molecules and disease phenotypes is non-trivial and presents both technical and conceptual challenges. Here, we discuss how these challenges could be addressed using genetically modified model organisms that have been instrumental in delineating the Ras-MAPK pathway and its roles during development. Focusing on studies in mice, zebrafish and Drosophila, we provide an up-to-date review of animal models of RASopathies at the molecular and functional level. We also discuss how increasingly sophisticated techniques of genetic engineering can be used to rigorously connect changes in specific components of the Ras-MAPK pathway with observed functional and morphological phenotypes. Establishing these connections is essential for advancing our understanding of RASopathies and for devising rational strategies for their management and treatment., (© 2015. Published by The Company of Biologists Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
8. Continual low-level MEK inhibition ameliorates cardio-facio-cutaneous phenotypes in zebrafish.
- Author
-
Anastasaki C, Rauen KA, and Patton EE
- Subjects
- Animals, Benzamides chemistry, Benzamides pharmacology, Benzamides therapeutic use, Diphenylamine analogs & derivatives, Diphenylamine chemistry, Diphenylamine pharmacology, Diphenylamine therapeutic use, Ectodermal Dysplasia embryology, Ectodermal Dysplasia pathology, Embryo, Nonmammalian drug effects, Embryo, Nonmammalian metabolism, Facies, Failure to Thrive embryology, Failure to Thrive pathology, Heart Defects, Congenital embryology, Heart Defects, Congenital pathology, Mitogen-Activated Protein Kinase Kinases metabolism, Phenotype, Protein Kinase Inhibitors chemistry, Proto-Oncogene Proteins B-raf metabolism, Small Molecule Libraries pharmacology, Ectodermal Dysplasia drug therapy, Ectodermal Dysplasia enzymology, Failure to Thrive drug therapy, Failure to Thrive enzymology, Heart Defects, Congenital drug therapy, Heart Defects, Congenital enzymology, Mitogen-Activated Protein Kinase Kinases antagonists & inhibitors, Protein Kinase Inhibitors pharmacology, Protein Kinase Inhibitors therapeutic use, Zebrafish embryology
- Abstract
Cardio-facio-cutaneous (CFC) syndrome is caused by germline mutations in KRAS, BRAF and MEK1/2. The highly selective and potent MEK inhibitors that have been developed as anti-cancer agents hold potential as therapeutics for CFC syndrome. We have previously shown that the effects of CFC mutations on zebrafish gastrulation can be prevented by a 1-hour treatment with MEK inhibitors within a specific developmental time-window. However, MEK activity is essential for normal development and PD0325901 treatment outside this treatment window leads to additional developmental defects in MEK-dependent tissues. We now test ten different doses of PD0325901 at six developmental time points and assess the effects on body axis length, heart development and craniofacial structures in zebrafish embryos. Notably, we find that a continuous low-level dose of PD0325901 that has only minor inhibition of MEK activity can prevent the action of both the common CFC BRAF(Q257R) kinase-active allele and the BRAF(G596V) kinase-impaired mutant allele through the first 5 days of development. These results provide a detailed study of the effects of PD0325901 in development and show that, unlike in cancer, which requires robust inhibition of MAPK signalling, a partial reduction in phospho-ERK1/2 activity is sufficient to moderate the developmental effects of BRAF(CFC) mutations.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.